International Organising Committee

Symposium Chairman

R. MOREIRA (University of Lisbon, Lisbon, Portugal)

Members

	B. CLEMENT (Kiel University, Kiel, Germany)
	G. COSTANTINO (University of Parma, Parma, Italy)
	P. JONES (University of Dundee, Lanarkshire, United Kingdom)
	H. P. MAERKI (F. Hoffmann-La Roche, Basel, Switzerland)
	E. OTTOW (Bayer HealthCare, Berlin, Germany)
	A. M. SILVA (University of Aveiro, Aveiro, Portugal)
	K. B. SIMONSEN (Lundbeck, Valby, Denmark)
	H. U. STILZ (Novo Nordisk, Malov, Denmark)
	H. TIMMERMAN (VU University Amsterdam, Amsterdam, The Netherlands)

Local Organising Committee

Members

	J. CAVALEIRO (University of Aveiro, Aveiro, Portugal)
	P. S. DA SILVA (Bial Ltd, S. Mamede do Coronado, Portugal)
	W. HEGGIE (Hovione, Loures, Portugal)
	A. M. LOBO (New University of Lisbon - FCT, Caparica, Portugal)
	M. MARQUES (Instituto Superior Técnico, ULisboa, Lisbon, Portugal)
	R. MOREIRA (University of Lisbon, Lisbon, Portugal)
	M. PINTO (Faculty of Pharmacy, University of Porto, Porto, Portugal)
	F. PROENÇA (University of Minho, Braga, Portugal)
	C. ROMAO (Alfama & ITQB, Oeiras, Portugal)
	M. L. SA E MELO (University of Coimbra, Coimbra, Portugal)
	A. M. SILVA (University of Aveiro, Aveiro, Portugal)
	S. SIMOES (Bluepharma & University of Coimbra, Coimbra, Portugal)

International Scientific Committee

Members

	K.-H. ALTMANN (SCS DMCCB & Swiss Federal Institute of Technology, Zurich, Switzerland)
	P. ARTURSON (University of Uppsala, Uppsala, Sweden)
	Y. P. AUBERSON (Novartis Institutes for BioMedical Research, Basel, Switzerland)
	S. BAGAL (Pfizer Neusentis, Cambridge, United Kingdom)
	B. BANG-ANDERSEN (H. Lundbeck A/S, Valby, Denmark)
	E. BANOGLU (Gazi University, Ankara, Turkey)
	E. BARREIRO (Federal University of Rio de Janeiro, Rio de Janeiro, Brazil)
	M. BLANCO-PILLADO (Eli Lilly and Company, Indianapolis, United States)
	M. BRANDS (Bayer Pharma AG, Wuppertal, Germany)
	A. BROWN (Pfizer Neusentis, London, United Kingdom)
	M. J. CAMARASA (IQM-CSIC, Madrid, Spain)
	N. CARRUTHERS (Johnson & Johnson R&D, San Diego, United States)
	G. CIRRINCIONE (University of Palermo, Palermo, Italy)
	S. CONWAY (University of Oxford, Oxford, United Kingdom)
	B. COX (Novartis Institutes for Biomedical Research, Brighton, United Kingdom)
	P. S. DA SILVA (Bial Ltd, S. Mamede do Coronado, Portugal)
	A. DAVIS (AstraZeneca, Mölndal, Sweden)
	G. DUBURS (Latvian Institute of Organic synthesis, Riga, Latvia)
	G. ECKER (University of Vienna, Vienna, Austria)
	P. ETTMAYER (Boehringer Ingelheim, Vienna, Austria)
	E. FERREIRA (University of Sao Paulo, Sao Paulo, Brazil)
	V. GABELICA MARKOVIC (Fidelta Ltd, Zagreb, Croatia)
	C. GARCIA-ECHEVERRIA (Sanofi, Vitry sur Seine, France)
	C. GENICOT (UCB Pharma, Braine-l'Alleud, Belgium)
	P. GEORGE (SCT & Independent Scientific Expert & Adviser, Longvilliers, France)
	M. HANN (GSK Medicines Research Centre, Stevenage, United Kingdom)
	R. HARTMANN (ElexoPharm, Saarbrücken, Germany)
	T. HOFFMANN (F. Hoffmann-La Roche, Basel, Switzerland)
	T. HÖGBERG (Leo Pharma, Ballerup, Denmark)
	A. P. IJZERMAN (University of Leiden, Leiden, The Netherlands)
	H. JHOTI (Astex Therapeutics, Cambridge, United Kingdom)
	K. JOZWIAK (Medical University of Lublin, Lublin, Poland)
	G. KESERU (Hungarian Academy of Sciences, Budapest, Hungary)
	G. KLEBE (Philipps-University Marburg, Marburg, Germany)
	A. KOUROUNAKIS (University of Athens, Athens, Greece)
	A. LEVITZKI (Hebrew University of Jerusalem, Jerusalem, Israel)
	J. MACK (Boehringer Ingelheim, Biberach an der Riss, Germany)
	M. MARQUES (Instituto Superior Técnico, ULisboa, Lisbon, Portugal)
	L. MEERPOEL (Janssen R&D, Beerse, Belgium)
	J. MESTRES (IMIM and University Pompeu Fabra, Barcelona, Spain)
	F. MICHELI (Aptuit, Verona, Italy)
	J. MINERS (Flinders University School of Medicine, Bedford Park, Australia)
	M. MISSBACH (Novartis, Basel, Switzerland)
	C. MONTANARI (University of Sao Paulo, Sao Paulo, Brazil)
	G. MÜLLER (Mercachem, Nijmegen, The Netherlands)
	R. NUDELMAN (Teva Pharmaceutical Industries, Petah Tikva, Israel)
	D. OLIVER (North-West University, Potchefstroom, South Africa)
	T. OOST (Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany)
	V. A. PALYULIN (Lomonosov Moscow State University, Moscow, Russia)
	Z. PAN (Peking University, Shenzhen, China)
	L. PETERLIN MASIC (University of Ljubljana, Ljubljana, Slovenia)
	M. PINTO (Faculty of Pharmacy, University of Porto, Porto, Portugal)
	A. T. PLOWRIGHT (AstraZeneca, Mölndal, Sweden)
	J. ROBERTSON (TES Pharma S.r.l., Corciano , Italy)
	I. ROZAS (Trinity College Dublin, Dublin, Ireland)
	G. SCHNEIDER (ETH Zürich, Zurich, Switzerland)
	N. SHIMMA (SynGen Consulting, Kanagawa, Japan)
	S. SIMOES (Bluepharma & University of Coimbra, Coimbra, Portugal)
	H. STEINHAGEN (Grünenthal, Verona, Italy)
	H. SUGA (University of Tokyo, Tokyo, Japan)
	G. TAMAGNAN (Institute for Neurodegenerative Disorders and Molecular NeuroImaging, LLC, New Haven, United States)
	A. THOMAS (F. Hoffmann-La Roche Ltd, Basel, Switzerland)
	A. TORRENS (Esteve, Barcelona, Spain)
	M. TOZER (Peakdale Molecular, Cambridge, United Kingdom)
	A. TSANTILI-KAKOULIDOU (University of Athens, Athens, Greece)
	K. URBAHNS (Merck KGaA, Darmstadt, Germany)
	S. VAN CALENBERGH (UGent, Ghent, Belgium)
	M. VARASI (European Institute of Oncology, Milano, Italy)
	G. L. VERDINE (Harvard University, Cambridge, United States)
	P. WARNER (Formerly with AstraZeneca, United Kingdom)
	A. WILLIAMS (Eli Lilly and Co Ltd, Surrey, United Kingdom)
	A. WOOD (Pfizer, Cambridge, United States)
	J. YLI-KAUHALUOMA (University of Helsinki, Helsinki, Finland)
	A. YONATH (Weizmann Institute of Science, Rehovot, Israel)
	M.-Q. ZHANG (Amgen China, Shanghai, China)